Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Clinical trial NCT04964934 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04964934
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

ER-Positive HER2-Negative Breast Cancer

Start date: 2021-06-30
Primary completion: 2025-06-30
Enrollment: 315

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.